In 1960 it became apparent that patients who had taken thalidomide regularly as a nocturnal sedative for some months might develop peripheral neuropathy (Florence, 1960; Kuenssberg, Simpson, and Stanton, 1961; Frenkel, 1961; Fullerton and Kremer, 1961;  Raffauf, 1961; Scheid, Wieck, Stammler, Kladetzky, and Gibbels, 1961) . In affected subjects sensory symptoms predominated; weakness was usually mild and involved proximal rather than distal muscles. Half the cases described by Frenkel (1961) and by Fullerton and Kremer (1961) had, in addition, evidence of mild pyramidal tract damage.
In 1961, Fullerton and Kremer reported that weakness improved rapidly when patients stopped taking thalidomide, but little improvement in sensation occurred-at least, during the first six months. Kremer (1965) later expressed doubt as to whether recovery of sensation ever occurs. In a four to five year clinical follow-up of 71 patients in Sweden, Hafstrom (1967) also found that weakness recovered, but in 55 of the patients there was no improvement in sensation, and the remainder had some residual sensory symptoms. Simpson (1963) and Hafstrom (1967) have both suggested that occasionally the condition may continue to progress after withdrawal of the drug.
Eleven of the 13 patients described by Fullerton and Kremer (1961) and 11 other patients have been seen at intervals for between four and six years after stopping thalidomide.
Their clinical, electrophysiological, and histological findings are presented below.
METHODS
ELECTROPHYSIOLOGY Since motor conduction velocity appeared to be unaffected in the previous study (Fullerton and Kremer, 1961) , this was not re-examined at followup. The electrophysiological study was, therefore, restricted to sensory nerves. Digital nerveaction potentials were recorded through saddle electrodes over the median nerve at the wrist, following stimulation of the nerves 'Part-time member, M.R.C. Toxicology Unit, Carshalton, Surrey. 'Overseas Scholar, Royal Australasian College of Physicians. of the index finger with ring electrodes, as described bv Dawson (1956) .
HISTOLOGY Biopsies were taken from the sural nerve at the level of the lateral malleolus at the ankle in six patients between two and six years after stopping thalidomide. In most cases only a fascicular biopsy was performed. The specimen was divided into two parts and each was stretched on a card frame.
The first portion was fixed in Flemming's solution, after which 51,u transverse sections were stained with Kultschitsky's haematoxylin as described by Gutmann and Sanders (1943) . All sections were photographed at a magnification of x 250 and enlarged to a magnification of x 500 for the estimation of fibre density. Selected bundles from each nerve were photographed at an enlargement of x 1,000 and from these diameters of approximately 1,009 fibres were measured. Details of photography, of the method of fibre counting, and of the measurement of fascicular area were similar to those described by Swallow (1966) and by O'Sullivan and Swallow (1968) . In the preparation of histograms all fibres with a diameter of 2, or less were grouped together. Larger fibres were subdivided into 1 groups. Fibre density for each size group was then calculated. The second portion of each nerve was fixed in 10% formol-saline. Part of this was stained with 1 % osmium tetroxide and single fibres were isolated by the method described by Thomas (1955) . The remainder was processed and transverse sections stained with haematoxylin and eosin.
RESULTS CLINICAL FEATURES Eleven of the patients reported here were previously described by Fullerton and Kremer (1961) . A further 11 patients were seen during the second half of 1961, after the original report had been prepared. Most of the patients were seen at six monthly or yearly intervals during the follow-up period. When the patients were first seen, the most distressing symptoms were painful paraesthesiae of the feet and hands, which were present in all cases. Muscle cramps were common, but not usually as distressing as the paraesthesiae. Actual muscle weakness occurred in a minority only. When present, weakness was usually mild; it was 543 also later in onset than ti to affect proximal muse affected patients, examini wasting in addition to ] jerks were often depresse portion of patients oth! and plantar responses es ination, a number of pa developed brittle finger palms was another occasi of these abnormalities in Table I he paraesthesiae and tended four patients who were severely affected had taken cles. In the most severely more than the usual dose of 100 mg nightly, and the ation revealed some muscle patient with the most extensive sensory loss had proximal weakness. Ankle taken 600 mg nightly. By contrast, four of the five ad or absent, but in a pro-mildly affected patients who had taken thalidomide er reflexes were increased for a year or more had received 100 mg nightly and xtensor. On general exam-the fifth patient had taken only 50 mg nightly.
[tients were found to have
The incidence of abnormal clinical features when nails; reddening of the the patients were first examined compared with those ional finding. The incidence at the time of the final follow-up examination four the 22 patients is shown in to six years later is shown in Table I . It can be seen that in 10 out of the 22 patients sensory loss accom-;aken thalidomide regularly panied by distressing paraesthesiae continued unpatient, who reported that changed. The sensory disturbance improved in ghtly for five months, was approximately a quarter of the patients and the n first seen. The remaining remaining quarter recovered completely. The paig thalidomide regularly for tient who had taken thalidomide for only five is, the mean duration being months and had very mild symptoms recovered us report by Fullerton and three months after stopping the drug. In the reygested that the total dura-maining patients a notable feature has been the ted to the severity of the slow tempo of recovery. Six patients improved the present larger series of gradually over a period of four years from the Llidomide for 12 months or time of stopping thalidomide. Two other patients In was apparent. Thus, the were still improving after six years. Three patients the drug had been taken did not begin to improve until three years after ed patients was 24 months; drug withdrawal, and two of them were still impatients the corresponding proving two years later. But the size of the nocturnal During the first few years after drug withdrawal dosage taken-did appear a number of patients complained of an increase in nining the severity of the severity of their sensory symptoms which led to the ible II). For example, all impression that the underlying neuropathy might have worsened. However, the distribution of paraesthesiae did not alter and there was no objective 3LE I increase in sensory loss. The complaint of increase [CAL FEATURES AT FIRST VISIT in paraesthesiae in the early part of the follow-up AMINATION 4-6 YEARS LATER period did not appear to affect the outcome, the Recovered Improved Unchanged final state of these patients being similar to those who did not complain of such symptoms.
In five patients with slight muscle weakness, 5 7 10 power had recovered completely after one to three there was only mild residual weakness but full motor recovery had not occurred six years later.
It can be seen from Table I that pyramidal signs disappeared in all except one patient, who continued to have extensor plantar responses. Ankle jerks were initially absent in three patients and did not return in any of them. However, the ankle jerks did return to normal in three of the six patients in whom they were previously sluggish.
Nine patients had brittle finger nails and in six of them their nails returned to normal. Three patients who initially had red palms lost this sign. One patient developed diabetes. Her neuropathy failed to improve during the follow-up period, but it is not possible to say whether her diabetes might be responsible for this. (Fullerton and Kremer, 1961) .
As a standard examination at follow-up, the sensory action potential was recorded from the median nerve at the wrist after stimulation of the index finger. The measurement was made in 19 of the 22 patients at the time of the last follow-up examination. This had been done previously in eight of the patients at their first examination. In four of them, the amplitude of the action potential had been reduced and in the other four it had been absent. In only two patients did amplitude increase during the follow-up period, one of them having recovered clinically and the other having improved. The action Table III. tNormal range: 9 to 45 pY (Gilliatt and Sears, 1958 previous demyelination of a whole segment. However, these findings were rare and similar mild changes have been described in nerves from control subjects of similar ages (Lascelles and Thomas, 1966) . There was, thus, no evidence that thalidomide had produced segmental demyelination to a significant extent.
Further information was obtained from transverse sections of nerves stained for myelin. Fibre density and fibre diameter measurements were made and compared with control values for healthy subjects studied by O'Sullivan and Swallow (1968) using the same technique. Figure 1 shows a transverse section of the nerve of Mrs. A. compared with a nerve from a control subject of the same age. There are obviously fewer large diameter fibres in the pathological nerve, although the total myelinated fibre density (5X23 thousand fibres/sq. mm) is within the control range.
In Fig. 2 histograms of fibre diameter are shown for the six thalidomide nerves and compared with the mean histograms for eight control subjects under the age of 60 and eight control subjects aged 60 years and over. The two control histograms were constructed from the data given by O'Sullivan and Swallow (1968) . In both control groups the distribution of fibre diameter is bimodal, but it can be seen that the large fibre peak has been lost in all the pathological nerves and that there is a marked reduction in the number of fibres greater than 6,u.
In contrast to this, the small fibre peak is preserved and in two cases apparently increased (Mrs. A and Mrs. F.).
A change in fibre density could reflect either an alteration in fibre number or a change in fascicular area. The area of each fascicle for the control and thalidomide nerves are, therefore, shown in Fig. 3 in relation to the subject's age. There is no obvious difference between the two groups. The mean fascicular area for the control nerves is 0 099 sq. mm (S.D. + 0 069), and for the thalidomide nerves is 0-089 sq. mm (S.D. ± 0 063). The difference between the two means is not statistically significant.
In Fig. 4 fibre density, expressed as thousand fibres/sq. mm is plotted against the subject's age. In Fig. 4a it can be seen that, for the pathological nerves, total fibre density falls in the lower part of the control range or below it. There is, however, a marked reduction in density in only one nerve (Mrs. S.). On the other hand the density of 2-6/L fibres is not decreased in any of the nerves (Fig. 4b) , but is actually increased in two of them. In the absence of a significant change in fascicular area, the marked increase in small fibre denisty in these two cases (Mrs. A. and Mrs. F.) strongly suggests regeneration. These pathological findings will now be considered in relation to the clinical and electrical follow-up on the individual patients (Table V) was reduced to a greater extent than in any of the other nerves examined. This may be related to the severity of clinical involvement. Mrs. L. was only mildly affected while taking thalidomide; despite this, she did not improve during the five year follow-up period, but continued to complain of paraesthesiae and cramps, and to show a mild sensory deficit in the hands and feet. The nerve action potentials recorded from the median nerve at the last examination were within the normal range, but it can be seen from Fig. 2 that the large diameter peak in the histogram of the sural nerve was considerably reduced, whereas the small fibre peak was preserved. The difference between the electrical and histological findings may be related to the fact that the patient's symptoms and signs were predominantly in the lower limbs, whereas the electrical tests were done on the upper limb. Mrs. A. had severe sensory symptoms when she stopped taking thalidomide in 1961. She continued to complain of unremitting paraesthesiae for the next three years and there was no change in her neurological signs. In 1964, no sensory nerve action potential could be recorded from the median nerve at the wrist. At this time the sural nerve biopsy was carried out (Fig. 1 ). There were very few large 
DISCUSSION
Thalidomide (y-phthalimidoglutarimide) was recognized to have peculiar teratogenic properties in 1961, and, as a result of this, there has subsequently been considerable interest in its metabolism. Much is now known about its mode of breakdown and distribution in various animals (Schumacher, Smith, and Williams, 1965a and b; Fabro, Smith, and Williams, 1967a and b) . Because part of the thalidomide molecule is related to glutamic acid, it has been suggested that its toxicity depends on interference with normal glutamate metabolism. However, results of experiments to test this hypothesisat least as far as the embryopathy in animals is concerned-suggest that the toxicity is not primarily due to such an action (Fabro, Schumacher, Smith, and Williams, 1964; Hirschberg, Osmos, Bryant, and Ultmann, 1964; Fabro, Schumacher, Smith, Stagg, and Williams, 1965a; McColl, Globus, and Robinson, 1965 suggested that interaction with diamines might be biologically important (Fabro, Smith, and Williams, 1965b) , but, as yet, there is no experimental evidence to support this interesting suggestion. Even less is known about the biochemical basis for thalidomide neuropathy. Experimental work has been hampered by the difficulty in producing the neuropathy in animals. Diezel (1963) produced some morphological changes in posterior columns, spinal ganglion cells, and posterior roots of dogs given thalidomide for over a year, and Klinghardt (1966) was able to produce peripheral nerve degeneration in rats and mice by giving high doses of the drug for long periods. Other workers have been less successful in producing neuropathy in a wide variety of species (Staemmler and Lagler, 1965) .
The incidence of neuropathy among patients who took thalidomide is unknown, although at one time the manufacturers of Distaval suggested an incidence of 0 5% in patients who had taken the drug for two months or more. Data from the present study suggest that individual idiosyncrasy to the drug is unlikely to be important, since the severity of the neurological disturbance appears to be related to the dose and amount of drug taken.
There have been few opportunities for pathological study of the neurological changes in man. However, Klinghardt (1965 Klinghardt ( , 1966 (1964) showed that the diameter of the largest fibres recovered to within 10-15% of normal one year after a crush.
If failure of clinical recovery is to be attributed at least partly to persistent peripheral nerve abnormalities, the reasons for this must be considered. In many of the toxic neuropathies in which primary axonal degeneration occurs, a dying back process has been demonstrated whereby the greatest damage occurs at the peripheral ends of the longest fibres. This has been demonstrated following tri-orthocresyl phosphate (Cavanagh, 1964) and acrylamide (Fullerton and Barnes, 1966) (Gibbels, 1968) .
